Recently formed Dunad Therapeutics, Ltd. has pulled off something of a coup by signing a major licensing deal with Novartis AG for its platform to be used to develop orally bioavailable covalent and targeted protein degradation (TPD) drugs.
Dunad Bags Big Pharma Partner In Protein Degradation Deal With Novartis
$24m Upfront For UK Biotech
Dunad is out-licensing its targeted protein degradation and covalent drug platform to Novartis in a deal that could be worth up to $1.3bn.
